血清肌炎特异性抗体与肌炎相关性抗体在多发性肌炎中的表达量及临床意义  

The expression levels and clinical significance of serum anti-RO52,Jo-1,Mi-2,PL-7 and PL-12 antibodies in polymyositis

作　　者：胡雅宁 田淑芬 曹绪维 黄梅 关家荣 HU Yaning;TIAN Shufen;CAO Xuwei;HUANG Mei;GUAN Jiarong(School of Clinical Medicine,Guizhou Medical University,Guiyang 550004,China;The Affiliated Hospital of Guizhou Medical University,Guiyang 550004,China;Guizhou Guiqian International General Hospital,Guiyang 550024,China)

机构地区：[1]贵州医科大学临床医学院,贵州贵阳550004 [2]贵州医科大学附属医院,贵州贵阳550004 [3]贵州贵黔国际总医院,贵州贵阳550024

出　　处：《西部医学》2024年第3期387-392,共6页Medical Journal of West China

基　　金：国家自然科学基金资助项目(82060865)。

摘　　要：目的 探讨血清肌炎特异性抗体与肌炎相关性抗体(抗Ro52、Jo-1、Mi-2、PL-7、PL-12抗体)在多发性肌炎(PM)中的表达量及临床意义。方法 选取贵州医科大学附属医院2015年1月—2017年1月接诊的60例PM患者展开回顾性研究,将其设为观察组,另选取同期本院门诊体检中心接诊的60例健康体检者设为对照组。检测、比较两组血清抗Ro52、Jo-1、Mi-2、PL-7、PL-12抗体阳性率,比较PM患者中是否合并肺间质疾病(ILD)、心脏损害的血清抗Ro52、Jo-1、Mi-2、PL-7、PL-12抗体阳性率,对60例PM患者进行为期5年的随访,采用Kaplan-Meire法进行生存分析,以Graph Pad Prism8.0绘制生存曲线,绘制受试者工作曲线(ROC)计算曲线下面积(AUC),分析抗Ro52、Jo-1、Mi-2、PL-7、PL-12抗体对PM患者预后预测价值。结果 观察组血清抗Ro52、Jo-1、Mi-2、PL-7、PL-12抗体阳性率均高于对照组(P<0.05)。合并ILD组血清抗Ro52、Jo-1、Mi-2、PL-7、PL-12抗体阳性率均高于无ILD组(P<0.05)。合并心脏损害组血清抗Ro52、Jo-1、Mi-2、PL-7、PL-12抗体阳性率均高于无心脏损害组(P<0.05)。60例PM患者中位生存时间48.14个月,5年生存率为85.00%,抗Ro52、Jo-1、Mi-2、PL-7、PL-12抗体阴性、阳性组生存曲线无统计学差异(P>0.05)。抗Ro52、Jo-1、Mi-2、PL-7、PL-12抗体联合检测预测PM患者预后的AUC是0.795(95%CI:0.711~0.963),联合检测的灵敏度(90.34%)及特异度(88.14%)均高于单独检测(P<0.05)。结论 PM患者抗Ro52、Jo-1、Mi-2、PL-7、PL-12抗体阳性率较高,以上抗体联合检测可提高对PM患者预后预测效能,具有重要的指导价值。Objective To analyze the expression levels and clinical significance of serum anti-RO52,Jo-1,Mi-2,PL-7 and PL-12 antibodies in polymyositis(PM).Methods A retrospective study was conducted on 60 PM patients admitted to the Affiliated Hospital of Guizhou Medical University from January 2015 to January 2017,and they were selected as the observation group,and another 60 healthy patients admitted to our outpatient physical examination center during the same period were selected as the control group.The positive rates of serum anti-RO52,Jo-1,Mi-2,PL-7 and PL-12 were detected and compared between the two groups.The positive rates of serum anti-RO52,Jo-1,Mi-2,PL-7 and PL-12 antibodies in the ILD group and the heart injury group were compared.60 cases of PM patients were followed up for 5 years,and survival analysis was performed by Kaplan-Meire method.The survival curve was plotted using Graph Pad Prism8.0,and the area under the curve(AUC) was calculated by receiver operating curve(ROC).The predictive value of anti-RO52,Jo-1,Mi-2,PL-7 and PL-12 antibodies on the prognosis of PM patients was analyzed.Results The positive rates of anti-RO52,Jo-1,Mi-2,PL-7 and PL-12 antibodies in the observation group were higher than those in the control group(P<0.05).The positive rates of serum anti-RO52,Jo-1,Mi-2,PL-7 and PL-12 antibodies in ILD group were higher than those in non-ILD group(P<0.05).The positive rates of serum anti-RO52,Jo-1,Mi-2,PL-7 and PL-12 antibodies in patients with heart damage were higher than those in patients without heart damage(P<0.05).The median survival time of 60 PM patients was 48.14 months,and the 5-year survival rate was 85.00%.Comparison of survival curves between negative and positive groups of anti-RO52,Jo-1,Mi-2,PL-7 and PL-12 antibodies(P>0.05).The AUC of combined detection of anti-RO52,Jo-1,Mi-2,PL-7 and PL-12 antibodies to predict the prognosis of PM patients was 0.795(95% CI:0.711-0.963),The sensitivity(90.34%) and specificity(88.14%) of the combined detection of anti-RO52,Jo-1,Mi-2,PL-7 and PL-1

关 键 词：肌炎特异性抗体 肌炎相关性抗体 多发性肌炎 肺间质疾病 心脏损害 

分 类 号：R685.2[医药卫生—骨科学]